Drug Discovery

As AI-driven drug development gains momentum, the pharmaceutical industry must reconcile rapid digital innovation with the strict regulatory demands of healthcare safety. The current landscape is defined by a significant ideological divide between Silicon Valley’s exponential growth models and the

Reliability and standardization are the new metrics of success as the industry attempts to ensure that biological data is reproducible across different batches and global locations. This shift follows a decade of intense focus on the computational "dry lab" side of drug discovery, where artificial

Autonomous laboratories are reducing the cost of innovation by allowing researchers to explore broad scientific domains with a minimal number of physical experiments. This shift represents a fundamental transformation in how LG AI Research approaches machine intelligence, moving away from broad,

A strategic shift in customs policy has lowered barriers for essential drugs while simultaneously protecting local producers with higher tariffs on certain goods. This dual-track approach emerges as the nation grapples with a widening trade gap that is projected by BMI, a Fitch Solutions company,

Refining spray drying setups to enhance energy efficiency serves as a primary manufacturing lever for reducing the global warming potential of oral drug delivery components. This technical advancement reflects a broader trend where the pharmaceutical industry is navigating a pivotal transition to

Automated monitoring systems can track organoid morphology in real-time, providing critical data points that are nearly impossible to capture through manual inspection. This technological leap, driven by the collaboration between Molecular Devices and STEMCELL Technologies, addresses the historical